13 research outputs found
Teste de anticorpos antifosfolípídes e cistatina C em pacientes com esclerose múltipla
Cystatin C is considered the most important physiological inhibitor of endogenous cysteine proteases; the role of cystatin C is believed to be to modulate the activity of proteases secreted or released from
damaged cells or in the process of necrosis, therefore cystatins being fundamental regulatory processes and a potential prevention of local proteolytic damage. Antiphospholipid antibodies are used to
clarify the diagnosis of diseases like multiple sclerosis (MS) and other pathologies could present similar
symptoms or paraclinical findings. The objective of the present work is to analyze the concentration of cystatin C and the presence or absence of antiphospholipid antibodies in patients diagnosed with
relapsing remitting multiple sclerosis (RRMS) as markers of demyelization. This work was carried out jointly by the Vascular Risk Laboratory, the Laboratory of Autoimmunity and Multiple Sclerosis Unit,
Hospital Universitario Virgen Macarena in Seville in one year. Two types of people were selected: Group 1 (n = 30) RRMS group and a control group, n = 30. Cystatin C and antiphospholipid antibodies IgG and IgM, IgG and IgM anticardiolipin, β2 glycoprotein IgG and IgM were determined. Patients showed
negative titers of antiphospholipid antibodies IgG and IgM, IgG and IgM anticardiolipin, β2 glycoprotein IgG and IgM. Cystatin C concentration is lower in the group of patients diagnosed with MS, which could give rise to a decrease in the modulation of endogenous cysteine proteases. This would exacerbate the progress of demyelization in MS.YesLa cistatina C es considerada el inhibidor fisiológico más importante de las
proteasas de cisteína endógenas. Se cree que el papel de la cistatina C es el
de modular la actividad de las proteasas secretadas o liberadas de células
dañadas o en proceso de necrosis, siendo por tanto las cistatinas fundamentales
para los procesos de regulación y prevención del potencial daño
proteolítico local. Los anticuerpos antifosfolípidos se usan para esclarecer el
diagnóstico de esclerosis múltiple (EM) ya que existen patologías que pueden
cursar con sintomatología o hallazgos paraclínicos semejantes. El objetivo
de este trabajo fue analizar la concentración de cistatina C y la presencia
o ausencia de anticuerpos antifosfolipídicos en pacientes diagnosticados de
esclerosis múltiple remitente recurrente (EMRR) como marcadores de desmielinización.
Este trabajo se llevó a cabo conjuntamente por el laboratorio
de Riesgo Vascular, el laboratorio de Autoinmunidad y la Unidad de Esclerosis
Múltiple del Hospital Universitario Virgen Macarena de Sevilla, España,
con una duración de un año. Se seleccionaron dos tipos de poblaciones:
grupo 1, n=30 pacientes con EMRR y un segundo grupo, denominado grupo
control, n=30. Se determinó cistatina C y anticuerpos antifosfolípidos IgG e
IgM, anticuerpos anticardiolipina IgG e IgM y anticuerpos β2 glicoproteína
IgG e IgM. Los pacientes diagnosticados de EMRR presentan títulos negativos
de anticuerpos antifosfolípidos IgG e IgM, anticardiolipina IgG e IgM y
β2 glicoproteína IgG e IgM. La concentración de cistatina C es menor en el
grupo de pacientes diagnosticados de EM, lo que podría producir un déficit
en la modulación de las proteasas de cisteína endógenas. Dicha desmielinización
agudizaría el progreso de la EM
Prognostic Value of Serum Free Light Chains Measurements in Multiple Myeloma Patients - Fig 4
<p>A) Progression-free survival (PFS) of all patients based on International Staging System (ISS) (n = 180). B) PFS of patients in ISS-1 stratified by sFLCR (n = 56). C) PFS of patients in ISS-2 stratified by sFLCR (n = 65). D) PFS of patients in ISS-3 stratified by sFLCR (n = 59).</p
Comparison of the prognostic ability of the International Staging System (ISS) and New Staging System (NSS) using the Akaike Information Criterion (AIC) values.
<p>Comparison of the prognostic ability of the International Staging System (ISS) and New Staging System (NSS) using the Akaike Information Criterion (AIC) values.</p
Prognostic value of International Staging System (ISS) and stratified by sFLCR.
<p>Prognostic value of International Staging System (ISS) and stratified by sFLCR.</p
Prognostic value of sFLCR.
<p>(A) Overall Survival (OS) and (B) Progression-free survival (PFS) of all MM patients (n = 180) stratified according to a low (<47) or high (≥47) sFLCR.</p
Prognostic value of “New Staging System (NSS)” based on sFLCR and B2M for Overall Survival (OS) and Progression-Free Survival (PFS).
<p>Prognostic value of “New Staging System (NSS)” based on sFLCR and B2M for Overall Survival (OS) and Progression-Free Survival (PFS).</p
Prognostic value obtained with different sFLC cut-offs.
<p>Prognostic value obtained with different sFLC cut-offs.</p
Univariate and multivariate analysis of prognostic factors for Overall Survival (OS) and Progression-free Survival (PFS) in patients with newly diagnosed MM (n = 180).
<p>Univariate and multivariate analysis of prognostic factors for Overall Survival (OS) and Progression-free Survival (PFS) in patients with newly diagnosed MM (n = 180).</p
Correlation analysis between clinical parameters of the disease and sFLCR, sFLC kappa and sFLC lambda levels.
<p>Correlation analysis between clinical parameters of the disease and sFLCR, sFLC kappa and sFLC lambda levels.</p